Growth Metrics

Summit Therapeutics (SMMT) Cash from Operations (2016 - 2026)

Summit Therapeutics filings provide 13 years of Cash from Operations readings, the most recent being 122291000.0 for Q1 2026.

  • Quarterly Cash from Operations fell 99.93% to 122291000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 384053000.0 through Mar 2026, down 121.82% year-over-year, with the annual reading at 322930000.0 for FY2025, 127.25% down from the prior year.
  • Cash from Operations hit 122291000.0 in Q1 2026 for Summit Therapeutics, down from 101938000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 5191000.0 in Q4 2022 and bottomed at 122291000.0 in Q1 2026.
  • Average Cash from Operations over 5 years is 41509941.18, with a median of 30134000.0 recorded in 2024.
  • The largest annual shift saw Cash from Operations soared 156.55% in 2022 before it crashed 474.86% in 2023.
  • Summit Therapeutics' Cash from Operations stood at 5191000.0 in 2022, then crashed by 474.86% to 19459000.0 in 2023, then plummeted by 150.13% to 48673000.0 in 2024, then crashed by 109.43% to 101938000.0 in 2025, then decreased by 19.97% to 122291000.0 in 2026.
  • Per Business Quant, the three most recent readings for SMMT's Cash from Operations are 122291000.0 (Q1 2026), 101938000.0 (Q4 2025), and 93080000.0 (Q3 2025).